lorazepam has been researched along with Cocaine-Related Disorders in 7 studies
Lorazepam: A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.
Cocaine-Related Disorders: Disorders related or resulting from use of cocaine.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dakwar, E | 2 |
| Levin, F | 1 |
| Foltin, RW | 1 |
| Nunes, EV | 2 |
| Hart, CL | 2 |
| Anerella, C | 1 |
| Levin, FR | 1 |
| Mathew, SJ | 1 |
| Richards, JR | 1 |
| Lange, RA | 1 |
| Arnold, TC | 1 |
| Horowitz, BZ | 1 |
| Morgan, PT | 1 |
| Malison, RT | 1 |
| Maccioli, GA | 1 |
| Volkow, ND | 1 |
| Wang, GJ | 1 |
| Fowler, JS | 1 |
| Hitzemann, R | 1 |
| Gatley, SJ | 1 |
| Dewey, SS | 1 |
| Pappas, N | 1 |
| Cawley, MJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Conscious Dying/Conscious Living: Ketamine-Assisted Psychotherapy (KAP) for Patients at End of Life-A Pilot Study for Palliative and Hospice Care[NCT05214417] | Phase 2 | 120 participants (Anticipated) | Interventional | 2022-05-01 | Not yet recruiting | ||
| The Effect of Ketamine on Reducing Cue Reactivity in Cocaine Users[NCT01790490] | Phase 2 | 8 participants (Actual) | Interventional | 2011-02-28 | Completed | ||
| Music as a Potential Intervention to Improve Hemodynamic Tolerability of Repetitive Sub-Anesthetic IV Ketamine Infusions in Bipolar and Unipolar Depression: A Pilot Study[NCT04701866] | 32 participants (Actual) | Interventional | 2021-01-11 | Completed | |||
| A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Dexmedetomidine (Precedex®), With Lorazepam Rescue, for the Management of Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)[NCT01362205] | Phase 4 | 49 participants (Actual) | Interventional | 2012-03-31 | Terminated (stopped due to DSMB recommendation for slow enrollment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Serial visual analogue scale (VAS) scores for craving elicited by cocaine cue: units on a scale (0-200), high is worse. Scores are obtained at baseline and at 24 hours after the infusion. (NCT01790490)
Timeframe: Baseline and 24 hours after infusion
| Intervention | units on a scale (0-200), high is worse (Median) |
|---|---|
| Ketamine Infusion 0.41 mg/kg Over 52 Minutes (K1) | 126 |
| Ketamine Infusion 0.71 mg/kg Over 52 Minutes (K2) | 18 |
| Lorazepam Infusion 2 mg/kg Over 52 Minutes (LZP) | 16 |
Motivation score obtained from the University of Rhode Island Change Assessment (URICA). Scores are obtained at baseline and at 24 hours after each infusion. The scores are 0-13, with higher scores indicating greater motivation. The analysis is within-subject. Scores included below are means; higher scores represent higher motivation to quit than do lower scores. (NCT01790490)
Timeframe: Baseline and 24 hours post-infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine Infusion 0.41 mg/kg Over 52 Minutes (K1) | 4.35 |
| Lorazepam Infusion 2 mg/kg Over 52 Minutes (LZP) | 3.2 |
| Lorazepam Infusion 2 mg/kg Over 52 Minutes (LZP) Following K1 | 4.2 |
Minnesota Detoxification Scale (MINDS) min score 0, max score 46. The higher the score, the worse the symptoms of AWS/AWD. (NCT01362205)
Timeframe: up to 28 days
| Intervention | units on a scale (Median) |
|---|---|
| Dexmedetomidine | 8.2 |
| Placebo | 9.4 |
A ventilator day is counted for any use of invasive mechanical ventilation during a calendar day (NCT01362205)
Timeframe: up to 28 days
| Intervention | days (Median) |
|---|---|
| Dexmedetomidine | 27.5 |
| Placebo | 28.0 |
(NCT01362205)
Timeframe: Up to 28 days
| Intervention | USD (Median) |
|---|---|
| Dexmedetomidine | 81234 |
| Placebo | 91651 |
(NCT01362205)
Timeframe: up to 28 Days
| Intervention | Dollar (United States) (Median) |
|---|---|
| Dexmedetomidine | 3482 |
| Placebo | 4461 |
The Beck Anxiety Inventory is a validated questionnaire used to measure severity of anxiety (min score 0, max score 63). The higher the score the greater the severity of anxiety. A score of 30-63 indicates severe anxiety, 17-29 moderate anxiety, 10-16 mild anxiety and 0-9 minimal anxiety. (NCT01362205)
Timeframe: Up to 28 days.
| Intervention | units on a scale (Mean) |
|---|---|
| Dexmedetomidine | 30.3 |
| Placebo | 21.6 |
The Beck Depression Inventory is a validated questionnaire used to measure severity of depression (min score 0, max score 63). The higher the score the greater the severity of depression. A score of 30-63 indicates severe depression, 19-29 moderate depression, 10-18 mild depression and 0-9 minimal depression. (NCT01362205)
Timeframe: Up to 28 days.
| Intervention | units on a scale (Mean) |
|---|---|
| Dexmedetomidine | 26.5 |
| Placebo | 21.4 |
The Mini Mental State Examination or Folstein test is a validated 30-point questionnaire used to measure cognitive impairment (min score 0, max score 30). A score of 24 points (out of a max of 30) indicates normal cognition, less than or equal to 9 points indicates severe impairment, 10-18 indicates moderate impairment and 19-23 mild impairment. (NCT01362205)
Timeframe: up to 28 days
| Intervention | units on a scale (Mean) |
|---|---|
| Dexmedetomidine | 25.8 |
| Placebo | 23.1 |
PTSD checklist consists of 17 questions graded on a scale of 1 to 5. The PTSD score is comprised from the sum of the scores 17 questions. The PTSD score has possible values from to 17 to 85 with higher values indicating greater symptom severity. (NCT01362205)
Timeframe: Up to 28 days
| Intervention | units on a scale (Median) |
|---|---|
| Dexmedetomidine | 45.5 |
| Placebo | 32.5 |
A hospital day is counted for any time on a calendar day the patient is admitted to the hospital. Hospital days are inclusive of ICU days. (NCT01362205)
Timeframe: up to 28 days
| Intervention | days (Median) |
|---|---|
| Dexmedetomidine | 8.0 |
| Placebo | 12.0 |
(NCT01362205)
Timeframe: up to 28 days in hours
| Intervention | hours (Median) |
|---|---|
| Dexmedetomidine | 79.2 |
| Placebo | 104.9 |
The Confusion Assessment Method (CAM)-ICU is a validated instrument used to detect the presence or absence of delirium in the ICU. A delirium free day is counted for any day a patient is negative by the CAM-ICU. The higher the number of CAM-ICU negative days indicates the more days a patient was able to think clearly. (NCT01362205)
Timeframe: up to 28 days
| Intervention | days (Median) |
|---|---|
| Dexmedetomidine | 0.3 |
| Placebo | 0.3 |
3 trials available for lorazepam and Cocaine-Related Disorders
| Article | Year |
|---|---|
The effects of subanesthetic ketamine infusions on motivation to quit and cue-induced craving in cocaine-dependent research volunteers.
Topics: Adult; Behavior, Addictive; Cocaine-Related Disorders; Craving; Cross-Over Studies; Cues; Dose-Respo | 2014 |
The effects of subanesthetic ketamine infusions on motivation to quit and cue-induced craving in cocaine-dependent research volunteers.
Topics: Adult; Behavior, Addictive; Cocaine-Related Disorders; Craving; Cross-Over Studies; Cues; Dose-Respo | 2014 |
The effects of subanesthetic ketamine infusions on motivation to quit and cue-induced craving in cocaine-dependent research volunteers.
Topics: Adult; Behavior, Addictive; Cocaine-Related Disorders; Craving; Cross-Over Studies; Cues; Dose-Respo | 2014 |
The effects of subanesthetic ketamine infusions on motivation to quit and cue-induced craving in cocaine-dependent research volunteers.
Topics: Adult; Behavior, Addictive; Cocaine-Related Disorders; Craving; Cross-Over Studies; Cues; Dose-Respo | 2014 |
Therapeutic infusions of ketamine: do the psychoactive effects matter?
Topics: Adult; Anesthetics, Dissociative; Cocaine-Related Disorders; Crack Cocaine; Cues; Data Interpretatio | 2014 |
Pilot study of lorazepam and tiagabine effects on sleep, motor learning, and impulsivity in cocaine abstinence.
Topics: Adult; Cocaine-Related Disorders; Cognition Disorders; Disruptive, Impulse Control, and Conduct Diso | 2008 |
4 other studies available for lorazepam and Cocaine-Related Disorders
| Article | Year |
|---|---|
Dual cocaine and methamphetamine cardiovascular toxicity: rapid resolution with labetalol.
Topics: Administration, Intravenous; Adrenergic beta-Antagonists; Amphetamine-Related Disorders; Anti-Anxiet | 2017 |
Dexmedetomidine to facilitate drug withdrawal.
Topics: Alcohol Drinking; Blood Pressure; Cocaine-Related Disorders; Dexmedetomidine; Female; Heart Rate; Hu | 2003 |
Enhanced sensitivity to benzodiazepines in active cocaine-abusing subjects: a PET study.
Topics: Adult; Brain; Cocaine-Related Disorders; Female; Fluorodeoxyglucose F18; Glucose; Humans; Lorazepam; | 1998 |
Short-term lorazepam infusion and concern for propylene glycol toxicity: case report and review.
Topics: Adult; Cocaine-Related Disorders; Critical Care; Diabetic Ketoacidosis; Excipients; Female; Hemodyna | 2001 |